ReviewPharmacy (Basel, Switzerland)2015
Posaconazole: An Update of Its Clinical Use.
Review in Pharmacy (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Phase 2, open-label, noncomparative clinical trial evaluating safety and efficacy of posaconazole in pediatric patients with proven/probable invasive aspergillosis or possible invasive fungal disease.Antimicrobial agents and chemotherapy · 2026Trial
- Acute fungal post-cataract endophthalmitis in the endophthalmitis management study: EMS report 7.BMJ open ophthalmology · 2025Trial
- Population Pharmacokinetic Model Assessment of the Effects of Body Weight on Risk of Drug-Drug Interactions After Posaconazole Discontinuation.Clinical and translational science · 2026Article
- Dual-Cross-Linked Alginate Hydrogels as a Strategy to Improve the Antifungal Properties of Posaconazole.Pharmaceutics · 2025Article
- Zinc Acetate as a Cross-Linking Agent in the Development of Enteric Microcapsules for Posaconazole.Pharmaceutics · 2025Article
- Role of Posaconazole Drug in the Treatment of Invasive Fungal Disease: A Review.Infectious disorders drug targets · 2025Review
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- Plasma Concentrations of Prophylactic Posaconazole and Risk Factors for Subtherapeutic Exposure in Taiwanese Patients with Hematologic Malignancies.Drug design, development and therapy · 2025Article
- Development of an HPLC-UV method for quantification of posaconazole in low-volume plasma samples: design of experiments and machine learning models.BMC chemistry · 2024Article
- Perspectives on blastomycosis in Canada in the face of climate change.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2024Article
- Recent Advances in Diagnosis and Treatment Approaches in Fungal Keratitis: A Narrative Review.Microorganisms · 2024Review
- Mucoadhesive Alginate/Pectin Films Crosslinked by Calcium Carbonate as Carriers of a Model Antifungal Drug-Posaconazole.Pharmaceutics · 2023Article
- Evaluation of antifungal susceptibility and clinical characteristics in fungal keratitis in a tertiary care center in North India.Indian journal of ophthalmology · 2022Article
- Electromembrane Extraction of Posaconazole for Matrix-Assisted Laser Desorption/Ionization Mass Spectrometric Detection.Membranes · 2022Article
- Emerging Antifungal Targets and Strategies.International journal of molecular sciences · 2022Review
- Sample Preparation of Posaconazole Oral Suspensions for Identification of the Crystal Form of the Active Pharmaceutical Ingredient.Molecules (Basel, Switzerland) · 2020Article
- Efficacy of Posaconazole Prophylaxis for Fungal Disease in Hematology Patients Treated With Chemotherapy and Transplantation: An Open-Label, Prospective, Observational Study.Frontiers in microbiology · 2020Article
- Characterization of Phase Transformations for Amorphous Solid Dispersions of a Weakly Basic Drug upon Dissolution in Biorelevant Media.Pharmaceutical research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posaconazole (PCZ) is a relatively new addition to the azole antifungals. It has fungicidal activities against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.